Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Sep 08, 2024 5:06pm
192 Views
Post# 36214000

Thankfully we have Turkey

Thankfully we have TurkeyCalgary site was announced 26 weeks ago, yes you read that correctly, 6 months ago! We still have yet to obtain the final approval so we can dose patients. The same goes for the two Toronto sites except we are even further behind.

I have my doubts we will ever dose a patient in our AKI trial with Metablok. The Canadian approval system is broken as is the entire Health care system, this is no fsult of Arch management but clarly highlights why big pharma avoids Canada for drug trials.

This brings me to the Pontiac trial using Cilastatin, now this is not a trial initiated by Arch but we are participating. The previous press releases suggest this trial will commence in fall of 2025 but we have yet to see any news releases outlining sites that will be participating or any updates regarding ethics approvals. So lets assume they have yet to finalize sites and have not submitted for ethics approval.

The Pontiac trial in my opinion is 12 months away from dosing and we are well into 2027 before this trial is completed and into 2028 before we see data.

We have pushed all our chips in on Turkey, it lwould be nice to get an update on where we stand in Turkey. Please remember they initially had 6 sites in Turkey and out of the blue management mentioned in a an unrelated news release about pontiac trial that they were currently dosing at 5 sites in Turkey.

Management in my opinion were not transparent and tried to hide the fact that they dropped one site. Now my question is are we to believe we are dosing at 5 sites in Turkey or did they drop more????

We need communication and updates on our AkI trial. How many sites are currently dosing and how many patients have been dosed.

Its time management dtepped up and communicated to tge public markets and their shareholders. It is clearly obvious why we are severely undervalued and have no interest on the buy side. We have one analyst. We do not seem to promote the company or the science, we dont attend conferences.

Arch needs to start behaving like a public company and update investors!


<< Previous
Bullboard Posts
Next >>